ACHC · Acadia Healthcare Company, Inc.

The thesis

Acadia Healthcare's recovery case rests on the fiscal 2026 earnings outlook it raised in July, and the third-quarter report on 4 November 2026 settles whether that outlook holds. The adjusted close was $29.90 on 27 October 2026, 16.0% below the $35.61 52-week high.

The company announced on 13 October 2026 that it will release third-quarter results after the market closes on 4 November 2026, with a call at 9:00 a.m. Eastern on 5 November 2026. The shares closed at $31.67 on 14 October 2026, so part of the mid-October rise has since reversed. The 14-day relative strength index (RSI), a gauge of how fast a price has moved, reads 53.5, down from 74.3 on 14 October 2026.

The narrative is maturing: the turnaround story is well known, and no new company filing, guidance or results have appeared since the 23 September 2026 derivative-settlement 8-K. The rating stays low. The case is real but more likely to lag than to lead the S&P 500 over the next three months, and the report on 4 November 2026 is a two-sided event.

Bullish and bearish views on Acadia Healthcare Company, Inc.

The bull case on Acadia Healthcare Company, Inc. (ACHC), in brief: Management raised the annual outlook. The bear case: Liability costs keep absorbing earnings.

Bull case

• Management raised the annual outlook. The 28 July 2026 results lifted fiscal 2026 adjusted EBITDA (earnings before interest, taxes, depreciation and amortization) guidance to $590–615 million from $580–615 million. Adjusted earnings per share guidance rose to $1.45–1.60 from $1.35–1.60.

• Analyst targets sit above the price. Raymond James kept a $39 target on about 28 September 2026. In July, KeyBanc set $40, UBS $39, Guggenheim $38 and TD Cowen $36 (Benzinga, 9 July to 20 July 2026). Leerink raised its target to $33 from $30 on 23 September 2026.
• Large institutions added shares. MarketBeat reported on 14 October 2026 that BlackRock bought $441.7 million and Jefferies $106.5 million of the stock in the second quarter.
• Derivative litigation is moving toward closure. Defendants will pay Acadia $12 million plus governance reforms, preliminarily approved on 1 September 2026 (company 8-K, 23 September 2026).

Bear case

• Liability costs keep absorbing earnings. Professional and general liability costs rose $39.3 million in the second quarter, including a $28.6 million reserve adjustment for expected settlements.
• Legal exposure remains open. A jury returned a $105 million verdict on 12 May 2026 in the Fashion Valley case, now under post-trial motions and appeal. A Department of Justice grand-jury subpoena and an SEC inquiry are unresolved.
• Consensus is not bullish. MarketBeat's 14 October 2026 tally shows 8 Buy, 5 Hold and 2 Sell ratings, a "Hold" consensus and an average target of $30.69, close to the $29.90 close on 27 October 2026.
• Later settlement figures were not available for this note.

Price setup

The $29.90 close on 27 October 2026 sits above the 50-day average of $28.90 and the 200-day average of $27.79 (both MarketBeat, 14 October 2026; both will have moved slightly since). The shares closed at $26.93 on 1 October 2026 and at $31.67 on 14 October 2026. The adjusted close is up 6.3% over three months.

The 52-week high is $35.61. The shares are 16.0% below it, so there is no wide gap above a rising average. Crowding evidence is mixed: the report is seven calendar days away, short interest was elevated at the last figure available, and the consensus target of $30.69 leaves little room between the price and the average analyst view.

A daily close below $27.50 would put the shares under the 200-day average and end the case as framed. A move back toward the $31.67 mid-October close would need the third-quarter report to confirm the guidance.

Catalysts, next 30 days

• 10 December 2026, derivative-settlement final-approval hearing in Nashville. This falls outside the 30-day window. The $12 million settlement closes if the court approves it.

Elapsed catalysts

• 4 November 2026, third-quarter 2026 results after the close. The report tests the $590–615 million adjusted EBITDA range, liability reserves and the timing of Florida supplemental payments. (passed 2d ago)
• 5 November 2026, earnings call at 9:00 a.m. ET. Management commentary on guidance, professional-liability costs and litigation follows the release. (passed 1d ago)

What would change the view

The case breaks if Acadia cuts fiscal 2026 adjusted EBITDA guidance below $590 million or adjusted EPS guidance below $1.45 in the 4 November 2026 release. A further professional-liability reserve adjustment of the size seen in the second quarter ($28.6 million) would also weaken it. So would an 8-K showing that the $105 million Fashion Valley verdict survived post-trial motions, or a federal settlement carrying a large penalty.

On price, a daily close below $27.50, under the 200-day average of $27.79 that MarketBeat reported on 14 October 2026, ends the case. The rating would rise if the third-quarter results hold the guidance range and show liability costs easing against the second quarter.

What it trades with

Acadia is a US operator of behavioral-health facilities, so its results depend on payer mix, state Medicaid supplemental payments and professional-liability costs more than on the broad technology-led market. No theme cluster currently carries the name. Other managed-care and health-services names can move on the same reimbursement and policy headlines, but no peer data is cited here.